An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Exclusion Criteria

• •History of surgery or trauma at the site examined by ultrasound (hand, elbow, knee, ankle, etc.);
• •Local injection of glucocorticoids or other drugs at the site examined by ultrasound in recent 6 weeks;
• •Peripheral neuropathy;
• •Use of IL-17 or IL-12/23 inhibitors in the last 12 months;Use of infliximab, adamumab, golimumab, and cetuzumab in the last 10 weeks;PUVA treatment for the last 4 weeks;Use of topical treatment or UVB phototherapy that may have an effect on psoriasis in the last 2 weeks;
• •recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurologic disease; evidence of active or latent or inadequately treated Mycobacterium tuberculosis; aspartate transaminase (AST) or alanine transaminase (ALT) \>3x upper limit of normal (ULN) at screening; estimated creatinine clearance \<40 mL/min.